Sucampo Pharmaceuticals submits supplemental new drug application for Lubiprostone to treat IBS-C

Sucampo Pharmaceuticals, Inc., (Sucampo Pharmaceuticals) today announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C). Lubiprostone, developed by Sucampo Pharmaceuticals, is currently approved for the treatment of Chronic Idiopathic Constipation in adults as AMITIZA (24 mcg) and is marketed by Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America, Inc., (Takeda) in the U.S. for that indication.

IBS-C has a significant impact on millions of Americans living with the condition, said Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals founder, chairman and chief executive officer. We are excited that the results of our clinical studies have led to the successful filing of a supplemental New Drug Application for a lower strength of lubiprostone [8 mcg, twice daily] for IBS-C. If approved, lubiprostone may offer a new treatment option for people living with this condition.

Approximately 58 million Americans have irritable bowel syndrome, with IBS-C accounting for approximately one-third of these cases. IBS-C symptoms include abdominal pain and discomfort associated with defecation or a change in bowel habits with features of disordered defecation.

The supplemental application is based on a clinical study program that included two Phase III, multi-center, double-blinded, randomized, placebo-controlled trials involving 1,171 adults, followed by one long-term, open-label safety and efficacy extension trial involving 522 adults diagnosed with IBS-C. In the two Phase III studies, patients received lubiprostone 8 mcg taken twice daily (783 adults) or placebo (388 adults) over a 12-week period. In both trials, patients receiving lubiprostone 8 mcg twice daily were nearly twice as likely to achieve an overall response that was statistica

Contact: Stephanie Donlan

Page: 1 2

Related medicine news :

1. Sucampo submits new drug application for lubiprostone
2. American Urological Association honors Novartis Pharmaceuticals with annual health science award
3. Takeda submits new drug application for extended-release type 2 diabetes medication, ACTOplus met
4. Takeda submits new drug application for combination type 2 diabetes medication
5. Penn critical-care physicians recommend strategies when facing requests to end supplemental oxygen
6. Patients receiving supplemental oxygen during surgery have reduced risk of wound infection
7. Brightening prospects of using fluorescent nanotubes in medical applications
8. Panbio files first patent application for Homogenous Assay Technology
9. LOral accepting applications for 2007 USA fellowships for Women in Science
10. NIH wrongly blamed for reduced success rate of grant applications
11. Magnet lab researcher exploring science behind commercial applications of liquid helium

Post Your Comments:

(Date:8/31/2020)... ... August 31, 2020 , ... Want to get moving, break ... Alliance Research Foundation (CPARF) is thrilled to launch its fourth annual STEPtember campaign in ... virtual challenge, STEPtember meets everyone wherever they are at this moment — encouraging people ...
(Date:8/31/2020)... ... August 31, 2020 , ... Smile Brands ... groups in the United States, today announced the grand opening of another affiliated ... , Patients will enjoy convenient hours, a comfortable office, and full-service care at ...
(Date:8/31/2020)... ... ... In an effort to give back to the community in which it serves, ... with a special new rate code to benefit children and families at Ronald ... will be applied to any room type, any time, now through the end of ...
(Date:8/29/2020)... (PRWEB) , ... August 29, 2020 , ... When professor ... perhaps with greater ease than most people would. Rather than become melancholic, however, he ... deep advice on achieving one’s dreams. Randy Pausch took a negative situation and turned ...
(Date:8/28/2020)... Calif. (PRWEB) , ... August 28, 2020 , ... ... cover a one-year subscription to a customized Lighthouse Health & Wellness mobile app ... support of this project. Motorola Solutions Foundation awards grants each year to organizations, ...
Breaking Medicine News(10 mins):
(Date:8/26/2020)... ... August 26, 2020 , ... ... Helps Sports Injuries. The infographic breaks down ways that chiropractors can help heal ... , According to ScripHessco “Athletes have an unusual amount of pressure and stress ...
(Date:8/26/2020)... ... August 26, 2020 , ... ... Services, Laboratory Testing division, expands its technology footprint with the addition of ... platforms available. With industry-leading biomarker solutions, complemented with traditional ligand-binding assays and ...
(Date:8/26/2020)... (PRWEB) , ... August 26, ... ... Holdings company today announced that it has entered into definitive agreement to ... CME/CE, primarily focused on pharmacists and pharmacy technicians. , CEA represents ...
Breaking Medicine Technology:
Cached News: